Drug intelligence / Profile preview

urapidil kalceks

Development stage
Unknown
Lead developer
Kalceks
Modality
Small Molecules
Administration
Intravenous
01

Overview

Urapidil Kalceks is a generic small molecule antihypertensive agent developed and manufactured by Kalceks. It features a unique dual mechanism of action, acting as a peripheral alpha-1 adrenergic receptor antagonist and a central 5-hydroxytryptamine receptor 1A (5-HT1A) agonist. The peripheral antagonism leads to vasodilation and reduced peripheral resistance, while the central agonism prevents the reflex increase in sympathetic tone typically associated with vasodilators. This combination allows for effective blood pressure reduction without significant reflex tachycardia. Urapidil Kalceks is approved for the treatment of hypertensive emergencies, severe and very severe hypertension, and perioperative hypertension, and is administered as an intravenous injection or infusion.

Brand names
Urapidil Kalceks
Other names
urapidil
02

Targets

HTR2A (Serotonin receptor 5-HT2A)ADRA1A (α1A)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))

Beyond the preview

Go deeper on urapidil kalceks.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on urapidil kalceks.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call